Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.45 |
| ▸ | HTR2B | P41595 | 4/20 | 0.45 |
| ▸ | NOS1 | P29475 | 3/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8912218 | 0.94 | HTR2C (0.46) | HTR2CHTR2BNOS1NOS3HTR2A | |
| SCHEMBL1953926 | 0.81 | CYP3A4 (0.44) | NOS1NOS3CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL6616471 | 0.78 | HTR2C (0.44) | HTR2CHTR2BNOS1NOS3HTR2A | |
| SCHEMBL1420634 | 0.78 | HTR2C (0.44) | HTR2CHTR2BNOS1NOS3TP53 | |
| SCHEMBL6158943 | 0.78 | NOS3 (0.36) | NOS1NOS3CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL2853069 | 0.77 | HTR2C (0.43) | HTR2CHTR2BNOS1NOS3TP53 | |
| Hydrochloric Acid SCHEMBL3450852 | 0.77 | HTR2C (0.43) | HTR2CHTR2BNOS1NOS3TP53 | |
| Hydrochloric Acid SCHEMBL21597931 | 0.76 | HTR2C (0.42) | HTR2CHTR2BNOS1NOS3TP53 | |
| SCHEMBL1952765 | 0.74 | CYP3A4 (0.46) | NOS1NOS3CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL297012 | 0.72 | HTR2C (0.45) | HTR2CHTR2BNOS1NOS3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0739891-B1 | Substituted heterocycles | ASTRAZENECA AB (SE) | 2005-01-19 | — | — | EP | claimed |
| EP-0680962-B1 | Heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | EP | claimed |
| EP-0734383-B1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | claimed |
| US-5739149-A | TREATING ASTHMA | ZENECA LIMITED (GB) | 1998-04-14 | — | — | US | claimed |
| EP-0739891-A2 | Substituted heterocycles | ZENECA LIMITED (GB) | 1996-10-30 | — | — | EP | claimed |
| EP-0680962-A2 | Heterocyclic compounds | ZENECA LIMITED (GB) | 1995-11-08 | — | — | EP | claimed |
| US-7368461-B2 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| EP-1444220-B1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2005-09-15 | — | — | US | disclosed |
| EP-0739891-B1 | Substituted heterocycles | ASTRAZENECA AB (SE) | 2005-01-19 | — | — | EP | disclosed |
| EP-1444220-A1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| EP-0680962-B1 | Heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003037889-A1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| EP-0734383-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1996-10-02 | — | — | EP | disclosed |
| US-5559131-A | ANTAGONISTS OF TACHYKININS AT THE NEUROKININ 2 RECEPTOR, ANTIASTHMA | ZENECA LIMITED (GB) | 1996-09-24 | — | — | US | disclosed |
| US-5559132-A | ANTAGONIST OF TACHYKININS AT THE NEUROKININ 2 RECEPTOR, ANTIASTHMA | ZENECA LIMITED (GB) | 1996-09-24 | — | — | US | disclosed |
| EP-0680962-A2 | Heterocyclic compounds | ZENECA LIMITED (GB) | 1995-11-08 | — | — | EP | disclosed |
| EP-0667858-A1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-08-23 | — | — | EP | disclosed |
| WO-1995016682-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1995-06-22 | — | — | WO | disclosed |
| WO-1994010146-A1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | TACR1, TACR2, BDKRB1 | HTR2C 667/4885HTR2B 264/4885NOS1 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.